Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109. Article uri icon

Overview

publication date

  • May 2, 2026

Identity

Scopus Document Identifier

  • 105037471553

Digital Object Identifier (DOI)

  • 10.1016/j.ctarc.2026.101220

PubMed ID

  • 42070952